{
  "disease_name": "Mucopolysaccharidosis type 4",
  "orpha_code": "582",
  "drugs": [
    {
      "name": "N-terminal hexaglutamine-tagged recombinant human N-acetylgalactosamine-6-sulfate sulfatase",
      "substance_url": "/en/drug/substance/170129?name=582&mode=orpha&region=&status=all",
      "substance_id": "170129",
      "regulatory_url": "/en/drug/regulatory/180793?name=582&mode=orpha&region=",
      "regulatory_id": "180793",
      "orpha_substance_code": "ORPHA:582",
      "details": [
        "N-terminal hexaglutamine-tagged recombinant human N-acetylgalactosamine-6-sulfate sulfatase(Medicinal product                        - 27/02/2009)Disease(s) concernedORPHA:582 Mucopolysaccharidosis type 4",
        "N-terminal hexaglutamine-tagged recombinant human N-acetylgalactosamine-6-sulfate sulfatase(Medicinal product                        - 27/02/2009)",
        "(Medicinal product                        - 27/02/2009)",
        "Disease(s) concernedORPHA:582 Mucopolysaccharidosis type 4",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/170129?name=582&mode=orpha&region=&status=all",
          "text": "N-terminal hexaglutamine-tagged recombinant human N-acetylgalactosamine-6-sulfate sulfatase",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/582",
          "text": "ORPHA:582 Mucopolysaccharidosis type 4",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/180793?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "VIMIZIM",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/404819?name=582&mode=orpha&region=",
      "regulatory_id": "404819",
      "orpha_substance_code": "ORPHA:309297",
      "details": [
        "VIMIZIM(Tradename                        - 28/04/2014)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "VIMIZIM(Tradename                        - 28/04/2014)",
        "(Tradename                        - 28/04/2014)",
        "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/404818?name=582&mode=orpha&region=&status=all",
          "text": "VIMIZIM",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309297",
          "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/404819?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with a lentiviral vector encoding for the N-acetylgalactosamine 6-sulfatase cDNA",
      "substance_url": "/en/drug/substance/629835?name=582&mode=orpha&region=&status=all",
      "substance_id": "629835",
      "regulatory_url": "/en/drug/regulatory/629838?name=582&mode=orpha&region=",
      "regulatory_id": "629838",
      "orpha_substance_code": "ORPHA:309297",
      "details": [
        "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with a lentiviral vector encoding for the N-acetylgalactosamine 6-sulfatase cDNA(Medicinal product                        - 10/08/2022)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with a lentiviral vector encoding for the N-acetylgalactosamine 6-sulfatase cDNA(Medicinal product                        - 10/08/2022)",
        "(Medicinal product                        - 10/08/2022)",
        "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/629835?name=582&mode=orpha&region=&status=all",
          "text": "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with a lentiviral vector encoding for the N-acetylgalactosamine 6-sulfatase cDNA",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309297",
          "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/629838?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "adeno-associated virus serotype 9 vector containing human n-acetylgalactosamine-6-sulfate sulfatase gene",
      "substance_url": "/en/drug/substance/588825?name=582&mode=orpha&region=&status=all",
      "substance_id": "588825",
      "regulatory_url": "/en/drug/regulatory/588832?name=582&mode=orpha&region=",
      "regulatory_id": "588832",
      "orpha_substance_code": "ORPHA:309297",
      "details": [
        "adeno-associated virus serotype 9 vector containing human n-acetylgalactosamine-6-sulfate sulfatase gene(Medicinal product                        - 09/01/2020)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "adeno-associated virus serotype 9 vector containing human n-acetylgalactosamine-6-sulfate sulfatase gene(Medicinal product                        - 09/01/2020)",
        "(Medicinal product                        - 09/01/2020)",
        "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/588825?name=582&mode=orpha&region=&status=all",
          "text": "adeno-associated virus serotype 9 vector containing human n-acetylgalactosamine-6-sulfate sulfatase gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309297",
          "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/588832?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Elosulfase alfa",
      "substance_url": "/en/drug/substance/189159?name=582&mode=orpha&region=&status=all",
      "substance_id": "189159",
      "regulatory_url": "/en/drug/regulatory/211596?name=582&mode=orpha&region=",
      "regulatory_id": "211596",
      "orpha_substance_code": "ORPHA:309297",
      "details": [
        "Elosulfase alfa(Medicinal product                        - 24/07/2009)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "Elosulfase alfa(Medicinal product                        - 24/07/2009)",
        "(Medicinal product                        - 24/07/2009)",
        "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/189159?name=582&mode=orpha&region=&status=all",
          "text": "Elosulfase alfa",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309297",
          "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/211596?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "VIMIZIM",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/393922?name=582&mode=orpha&region=",
      "regulatory_id": "393922",
      "orpha_substance_code": "ORPHA:309297",
      "details": [
        "VIMIZIM(Tradename                        - 24/02/2014)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "VIMIZIM(Tradename                        - 24/02/2014)",
        "(Tradename                        - 24/02/2014)",
        "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/404818?name=582&mode=orpha&region=&status=all",
          "text": "VIMIZIM",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309297",
          "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/393922?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "VIMIZIM",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/405043?name=582&mode=orpha&region=",
      "regulatory_id": "405043",
      "orpha_substance_code": "ORPHA:309297",
      "details": [
        "VIMIZIM(Tradename                        - 14/02/2014)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "VIMIZIM(Tradename                        - 14/02/2014)",
        "(Tradename                        - 14/02/2014)",
        "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/404818?name=582&mode=orpha&region=&status=all",
          "text": "VIMIZIM",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309297",
          "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/405043?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-associated virus 8 vector expressing functional human cDNA encoding the N-acetylgalactosamine-6-sulfate sulfatase",
      "substance_url": "/en/drug/substance/688296?name=582&mode=orpha&region=&status=all",
      "substance_id": "688296",
      "regulatory_url": "/en/drug/regulatory/688384?name=582&mode=orpha&region=",
      "regulatory_id": "688384",
      "orpha_substance_code": "ORPHA:309297",
      "details": [
        "Adeno-associated virus 8 vector expressing functional human cDNA encoding the N-acetylgalactosamine-6-sulfate sulfatase(Medicinal product                        - 20/09/2024)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "Adeno-associated virus 8 vector expressing functional human cDNA encoding the N-acetylgalactosamine-6-sulfate sulfatase(Medicinal product                        - 20/09/2024)",
        "(Medicinal product                        - 20/09/2024)",
        "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/688296?name=582&mode=orpha&region=&status=all",
          "text": "Adeno-associated virus 8 vector expressing functional human cDNA encoding the N-acetylgalactosamine-6-sulfate sulfatase",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309297",
          "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/688384?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Elosulfase alfa",
      "substance_url": "/en/drug/substance/189159?name=582&mode=orpha&region=&status=all",
      "substance_id": "189159",
      "regulatory_url": "/en/drug/regulatory/405044?name=582&mode=orpha&region=",
      "regulatory_id": "405044",
      "orpha_substance_code": "ORPHA:309297",
      "details": [
        "Elosulfase alfa(Medicinal product                        - 15/05/2009)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "Elosulfase alfa(Medicinal product                        - 15/05/2009)",
        "(Medicinal product                        - 15/05/2009)",
        "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/189159?name=582&mode=orpha&region=&status=all",
          "text": "Elosulfase alfa",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309297",
          "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/405044?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Elosulfase alfa",
      "substance_url": "/en/drug/substance/189159?name=582&mode=orpha&region=&status=all",
      "substance_id": "189159",
      "regulatory_url": "/en/drug/regulatory/393923?name=582&mode=orpha&region=",
      "regulatory_id": "393923",
      "orpha_substance_code": "ORPHA:309297",
      "details": [
        "Elosulfase alfa(Medicinal product                        - 15/05/2009)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "Elosulfase alfa(Medicinal product                        - 15/05/2009)",
        "(Medicinal product                        - 15/05/2009)",
        "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/189159?name=582&mode=orpha&region=&status=all",
          "text": "Elosulfase alfa",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/309297",
          "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/393923?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "PLERIXAFOR ACCORD",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/642317?name=582&mode=orpha&region=",
      "regulatory_id": "642317",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
        "(Tradename                        - 16/12/2022)",
        "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/642316?name=582&mode=orpha&region=&status=all",
          "text": "PLERIXAFOR ACCORD",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/29073",
          "text": "ORPHA:29073 Multiple myeloma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/223735",
          "text": "ORPHA:223735 Lymphoma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/642317?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Thiotepa Riemser",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/610636?name=582&mode=orpha&region=",
      "regulatory_id": "610636",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Thiotepa Riemser(Tradename                        - 26/03/2021)",
        "(Tradename                        - 26/03/2021)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/610616?name=582&mode=orpha&region=&status=all",
          "text": "Thiotepa Riemser",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/610636?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "motixafortide",
      "substance_url": "/en/drug/substance/588874?name=582&mode=orpha&region=&status=all",
      "substance_id": "588874",
      "regulatory_url": "/en/drug/regulatory/661036?name=582&mode=orpha&region=",
      "regulatory_id": "661036",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "motixafortide(Medicinal product                        - 12/01/2024)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "motixafortide(Medicinal product                        - 12/01/2024)",
        "(Medicinal product                        - 12/01/2024)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/588874?name=582&mode=orpha&region=&status=all",
          "text": "motixafortide",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/661036?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
      "substance_url": "/en/drug/substance/589233?name=582&mode=orpha&region=&status=all",
      "substance_id": "589233",
      "regulatory_url": "/en/drug/regulatory/589234?name=582&mode=orpha&region=",
      "regulatory_id": "589234",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)",
        "(Medicinal product                        - 20/04/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589233?name=582&mode=orpha&region=&status=all",
          "text": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589234?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
      "substance_url": "/en/drug/substance/589056?name=582&mode=orpha&region=&status=all",
      "substance_id": "589056",
      "regulatory_url": "/en/drug/regulatory/589057?name=582&mode=orpha&region=",
      "regulatory_id": "589057",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)",
        "(Medicinal product                        - 24/03/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589056?name=582&mode=orpha&region=&status=all",
          "text": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589057?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Burixafor",
      "substance_url": "/en/drug/substance/689505?name=582&mode=orpha&region=&status=all",
      "substance_id": "689505",
      "regulatory_url": "/en/drug/regulatory/689915?name=582&mode=orpha&region=",
      "regulatory_id": "689915",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Burixafor(Medicinal product                        - 22/10/2024)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Burixafor(Medicinal product                        - 22/10/2024)",
        "(Medicinal product                        - 22/10/2024)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/689505?name=582&mode=orpha&region=&status=all",
          "text": "Burixafor",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/689915?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=582&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641081?name=582&mode=orpha&region=",
      "regulatory_id": "641081",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=582&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641081?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=582&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641075?name=582&mode=orpha&region=",
      "regulatory_id": "641075",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=582&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641075?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Treosulfan",
      "substance_url": "/en/drug/substance/90799?name=582&mode=orpha&region=&status=all",
      "substance_id": "90799",
      "regulatory_url": "/en/drug/regulatory/136690?name=582&mode=orpha&region=",
      "regulatory_id": "136690",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Treosulfan(Medicinal product                        - 08/04/2015)Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Treosulfan(Medicinal product                        - 08/04/2015)",
        "(Medicinal product                        - 08/04/2015)",
        "Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/90799?name=582&mode=orpha&region=&status=all",
          "text": "Treosulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/213500",
          "text": "ORPHA:213500 Rare ovarian cancer",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/136690?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "busulfan",
      "substance_url": "/en/drug/substance/46335?name=582&mode=orpha&region=&status=all",
      "substance_id": "46335",
      "regulatory_url": "/en/drug/regulatory/131973?name=582&mode=orpha&region=",
      "regulatory_id": "131973",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "busulfan(Medicinal product                        - 21/04/1994)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "busulfan(Medicinal product                        - 21/04/1994)",
        "(Medicinal product                        - 21/04/1994)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/46335?name=582&mode=orpha&region=&status=all",
          "text": "busulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131973?name=582&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    }
  ],
  "processing_timestamp": "2025-07-07T05:59:53.629206",
  "run_number": 1,
  "total_drugs_found": 20,
  "search_url": "https://www.orpha.net/en/drug?diseaseName=Mucopolysaccharidosis+type+4&orphaCode=582&name=582&region=&mode=orpha&status=all",
  "search_params": {
    "diseaseName": "Mucopolysaccharidosis type 4",
    "orphaCode": "582",
    "name": "582",
    "region": "",
    "mode": "orpha",
    "status": "all"
  }
}